Product Candidates: Multiple iPSC Cell Therapy Programs. Target: Undisclosed. Application: Regenerative medicine

2023年5月20日 · Showcases gene circuit application in iPSC-derived cells in collaboration with BlueRock Therapeutics. Massively parallel and systematic engineering platform for highly compact, cell-type specific, and potent Smart Sensor promoters for …

Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials

2024年12月8日 · senti-202是一种逻辑门控的现货型car-nk细胞疗法候选产品，旨在选择性靶向并清除表达cd33和/或flt3的血液恶性肿瘤，如aml和骨髓增生异常综合症（mds），同时避免杀伤健康骨髓细胞。

2023年4月21日 · 除了老牌企业Century Therapeutics再次公布结果，对其iPSC衍生的细胞治疗平台进行了概念验证外，另一家企业Senti Bio则将逻辑门控技术与CAR-NK疗法相结合，展现了技术前瞻性。

2023年1月27日 · Our lead product candidate is SENTI-202 for the treatment of CD33 and/or FLT3 expressing hematologic malignancies, such as AML and MDS. Additionally, our SENTI-401 program is being designed for the treatment of colorectal cancer (CRC) and …

2021年5月26日 · BlueRock Therapeutics plans to apply Senti Bio’s Smart Sensor and Regulator Dial gene circuit technology platform towards the goal of developing highly sophisticated engineered cell therapies ...

as well as with Bayer and BlueRock around iPSC cell engineering. On Slide 6, I'm happy to introduce SENTI-202 which is a potentially first-in-class, selective, off-the-shelf cell therapy designed to overcome key outstanding problems in AML. Specifically SENTI-202 leverages healthy NK cells from selected adult donors and is genetically engineered

2023年5月20日 · Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages...

Senti Bio’s Internal Programs Focus on Oncology, Partnering to Support Non-Oncology Indications AML: Acute myeloid leukemia; MDS: Myelodysplastic syndrome; HCC: Hepatocellular carcinoma; CNS: Central nervous system 3